Proteasome proteolytic profile is linked to Bcr-Abl expression

Experimental Hematology

Volumn 37, Issue 3, 2009, Pages 357-366

  Crawford, Lisa J ^a   Windrum, Phlip ^a   Magill, Laura ^a   Melo, Junia V ^b   McCallum, Lynn ^a   McMullin, Mary F ^a   Ovaa, Huib ^c   Walker, Brian ^a   Irvine, Alexandra E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEASOME; PROTEASOME INHIBITOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 59749086449     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.11.004     Document Type: Article

References (53)

1. Lugo T.G., Pendergast A.M., Muller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
2. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
3. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
4. Adams J., Behnke M., Chen S., et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8 (1998) 333-338
5. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59 (1999) 2615-2622
6. Imajoh-Ohmi S., Kawaguchi T., Sugiyama S., Tanaka K., Omura S., and Kilkuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217 (1995) 1070-1077
7. Shinohara K., Tomoika M., Nakano H., Tone S., Ito H., and Kawashami S. Apoptosis induction resulting from proteasome inhibition. Biochem J 317 (1996) 385-388
8. Meng L., Kwok B.H., Sin N., and Crews C.M. Eponemycin exerts it antitumour effect through inhibition of proteasome function. Cancer Res 59 (1999) 2798-2801
9. Orlowski R.Z., Eswara J.R., Lafond-Walker A., Grever M.R., Orlowski M., and Dang C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58 (1998) 4342-4348
10. Nawrocki S.T., Sweeeny-Gotsch B., Takamori R., and McConkey D.J. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3 (2004) 59-70
11. Kane R.C., Farell A.T., Sridhara R., and Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12 (2006) 2955-2960
12. Faderl S., Rai K., Gribben J., et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107 (2006) 916-924
13. Kane R.C., Dagher R., Farell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13 (2007) 5291-5294
14. Musto P., Rossini F., Gay F., et al. Efficacy and safety of Bortezomib in patients with plasma cell leukemia. Cancer 109 (2007) 2285-2290
15. Katodritou E., Verrou E., Gastari V., Hadjiaggelidou C., Terpos E., and Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res 32 (2008) 1153-1156
16. Attar E.C., Deangelo D.J., Supko J.G., et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 14 (2008) 1446-1454
17. Guzman M.L., Swiderski C.F., Howard D.F., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A 99 (2002) 16220-16225
18. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
19. Dai Y., Rahmani M., Pei X.Y., Dent P., and Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 104 (2004) 509-518
20. Dasmahapatra G., Rahmani M., Dent P., and Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 107 (2006) 232-240
21. Magill L., Lynas J., Morris T.C., Walker B., and Irvine A.E. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Hematalogica 89 (2004) 1428-1433
22. Heinemeyer W., Fischer M., Krimmer T., Stachon U., and Wolf D.H. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J Biol Chem 272 (1997) 25200-25209
23. Cardozo C. Catalytic components of the bovine pituitary multicatalytic proteinase complex (proteasome). Enzyme Protein 47 (1993) 296-301
24. Kisselev A.F., Akopian T.N., Castillo V., and Goldberg A.L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 4 (1999) 395-402
25. Jager S., Groll M., Huber R., Wolf D.H., and Heinemeyer W. Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function. J Mol Biol 291 (1999) 997-1013
26. Kisselev A.F., Callard A., and Goldberg A.L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281 (2006) 8582-8590
27. Kraus M., Ruckrich T., Reich M., et al. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21 (2007) 84-92
28. Busse A., Kraus M., Na I.K., et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 112 (2008) 659-670
29. Pierce A., Owen-Lynch P., Spooncer E., Dexter T.M., and Whetton A.D. P210 bcr-abl expression in a primitive haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene 17 (1998) 667-672
30. Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96 (2000) 1070-1079
31. Lynas J., Harriott P., Healy A., McKervey A., and Walker B. Inhibitors of the chymotrypsin-like activity of the proteasome based on di- and tri-peptidyl α-keto aldehydes (glyoxals). Bioorg Med Chem Lett 8 (1998) 373-378
32. Muzio M., Stockwell B.R., Stennicke H.R., Salvesen G.S., and Dixit V.M. An induced proximity model for caspase-8 activation. J Biol Chem 273 (1998) 2962-2930
33. Berkers C.R., Verdoes M., Lichtman E., et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2 (2005) 357-362
34. Scherr M., Battmer K., Winkler T., Heidenreich O., Ganser A., and Eder M. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101 (2003) 1566-1569
35. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of real-time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia 17 (2003) 2318-2357
36. Chou T., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
37. Kumatori A., Tanaka K., Inamura N., et al. Abnormally high expression of proteasomes in leukaemic cells. Proc Natl Acad Sci U S A 87 (1990) 7071-7075
38. Andreu E.J., Lledo E., Poch E., et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65 (2005) 3264-3272
39. An W.G., Hwang S.G., Trepel J.B., and Blagosklonny M.V. Protease inhibitor induced apoptosis: Accumulation of wt p53, p21 WAF1/CIP1 and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14 (2000) 1276-1283
40. Heaney N.B., and Holyoake T.L. Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 25 (2007) 66-75
41. Dai Z., Quakenbush R.C., Courtney K.D., et al. Oncogenic abl and src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a ras-independent pathway. Genes Dev 12 (1998) 1415-1424
42. Tauchi T., Yoshimura A., and Ohyashiki K. CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Exp Hematol 29 (2001) 356-361
43. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
44. Yu C., Rahmani M., Almenara J., Subler M., et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and-resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 63 (2003) 2118-2126
45. Kano Y., Akutsu M., Tsunoda S., et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97 (2001) 1999-2007
46. Mow B.M., Chandra J., Svingen P., et al. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99 (2002) 664-671
47. Nagar B., Bornmann W.G., Pellicena P., et al. Crystal structures of the kinase domain of c-abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62 (2002) 4236-4243
48. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
49. Gatto S., Scappini B., Pham L., et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr-Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88 (2003) 853-863
50. Crawford L.J., Walker B., Ovaa H., et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341 and MG-132. Cancer Res 66 (2006) 6379-6386
51. Goldman J.M., and Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
52. Chauhan D., Hideshima T., and Anderson K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 95 (2006) 961-965
53. Kuhn D.J., Chen Q., Voorhees P.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110 (2007) 3281-3290